BioNTech, an immunotherapy company, agreed to acquire the Kite production facility and assets from Gilead Sciences, an American biopharmaceutical company. Financial terms were not disclosed. “The development of individualized cancer therapies is at the core of our work at BioNTech. The acquisition of the Kite facility and its individualized TCR platform allows us to accelerate the clinical development of our cell therapies in the US and advance at the forefront of individualized cell therapies. It also strengthens our presence in the US, building on our successful integration of adoptive T-cell and neoantigen TCR therapies as part of our acquisition of Neon Therapeutics last year," Ugur Sahin, BioNTech CEO.